Young patients with breastcancer can safely interrupt adjuvant endocrine therapy to attempt pregnancy without increasing their risk of breast cancer recurrence or new contralateral breast cancer.
Before the analysis, the risks associated with taking a break from endocrine therapy among young women with hormone receptor –positive breast cancer remained unclear.
at that time, showed that a temporary interruption of therapy to attempt pregnancy did not appear to lead to worse breast cancer outcomes. The 3-year incidence of breast cancer events was 8.9% in the treatment-interruption group compared with 9.2% among historical controls, which included women who would have met the entry criteria for the trial.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Inflation Data to be Watched as Fed Contemplates Pausing Rate HikesThe Labor Department is set to release the consumer-price index report for April on Wednesday.
Read more »
Film Seekers Boards VR Therapy Revenge Thriller ‘ClearMind’ – Cannes MarketEXCLUSIVE: Film Seekers has acquired international sales rights to dark-comedy-thriller ClearMind about a virtual reality therapy experiment that takes a deadly turn for a Cannes sales launch. The …
Read more »
Behavioral Therapy Reduces Long COVID Fatigue: StudyPeople with long COVID significantly reduced their fatigue after completing 17 weeks of cognitive behavioral therapy, compared to people with similar long COVID fatigue levels who didn't participate in therapy, a new study shows.
Read more »
Angela After Dark: Artificial intelligence and therapyIt looks like artificial intelligence is here to stay. Could it be beneficial or detrimental to traditional therapy?
Read more »
FDA declines to approve ImmunityBio's bladder cancer therapy, shares slumpImmunityBio Inc said on Thursday the U.S. Food and Drug Administration has declined to approve its combination therapy to treat a type of bladder cancer due to deficiencies in the company's application.
Read more »